Thermo Fisher Scientific to Acquire Transplant Diagnostics Leader One Lambda
By LabMedica International staff writers Posted on 18 Jul 2012 |
Thermo Fisher Scientific (Waltham, MA, USA) has signed a definitive agreement to acquire One Lambda (Canoga Park, CA, USA), pioneer and global leader in transplant diagnostics, for USD 925 million in cash. One Lambda, whose business generated revenue of USD 182 million in 2011, will become part of Thermo Fisher’s Specialty Diagnostics Segment.
One Lambda develops its own transplant diagnostic tests utilizing serological, molecular, ELISA, flow, and Luminex xMAP technologies. The company also manufactures laboratory instrumentation and computer software that are used to simplify and automate testing procedures and final test evaluations. The transaction is expected enhance Thermo Fisher's presence in specialty in vitro diagnostics as growth in transplant diagnostics is being driven by increasing global demand. The specialized technology supports a broad portfolio of high-margin reagents in HLA (human leukocyte antigen) typing and antibody detection. New workflow capabilities will be added, as One Lambda's pre- and posttransplant tests will complement Thermo Fisher’s existing immunosuppressant assays. Thermo Fisher expects to leverage its extensive commercial capabilities to accelerate growth in One Lambda’s existing portfolio, which is currently marketed primarily to physicians and laboratories in the USA.
"With its strong technology platform, high margin profile, and good growth prospects, the business is perfectly aligned with our specialty in vitro diagnostics strategy," said Marc N. Casper, president, and chief executive officer of Thermo Fisher. George M. Ayoub, cofounder, president, and chief executive officer of One Lambda, added "I believe that, together, we will […] accelerate growth and improve the success rate of transplantation."
The transaction, anticipated for completion in the fourth quarter of 2012, is expected to be immediately accretive upon close and to generate revenue and cost synergies for a total adjusted operating income benefit of approximately USD 15 million in 2015. Thermo Fisher also announced an authorization to repurchase an additional USD 500 million of shares of its own common stock. “The acquisition of One Lambda […] demonstrates our ongoing commitment to effectively deploying our capital to create shareholder value,” Casper said.
Related Links:
Thermo Fisher Scientific, Inc.
One Lambda, Inc.
One Lambda develops its own transplant diagnostic tests utilizing serological, molecular, ELISA, flow, and Luminex xMAP technologies. The company also manufactures laboratory instrumentation and computer software that are used to simplify and automate testing procedures and final test evaluations. The transaction is expected enhance Thermo Fisher's presence in specialty in vitro diagnostics as growth in transplant diagnostics is being driven by increasing global demand. The specialized technology supports a broad portfolio of high-margin reagents in HLA (human leukocyte antigen) typing and antibody detection. New workflow capabilities will be added, as One Lambda's pre- and posttransplant tests will complement Thermo Fisher’s existing immunosuppressant assays. Thermo Fisher expects to leverage its extensive commercial capabilities to accelerate growth in One Lambda’s existing portfolio, which is currently marketed primarily to physicians and laboratories in the USA.
"With its strong technology platform, high margin profile, and good growth prospects, the business is perfectly aligned with our specialty in vitro diagnostics strategy," said Marc N. Casper, president, and chief executive officer of Thermo Fisher. George M. Ayoub, cofounder, president, and chief executive officer of One Lambda, added "I believe that, together, we will […] accelerate growth and improve the success rate of transplantation."
The transaction, anticipated for completion in the fourth quarter of 2012, is expected to be immediately accretive upon close and to generate revenue and cost synergies for a total adjusted operating income benefit of approximately USD 15 million in 2015. Thermo Fisher also announced an authorization to repurchase an additional USD 500 million of shares of its own common stock. “The acquisition of One Lambda […] demonstrates our ongoing commitment to effectively deploying our capital to create shareholder value,” Casper said.
Related Links:
Thermo Fisher Scientific, Inc.
One Lambda, Inc.
Latest Industry News
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus
- AMP Publishes Best Practice Guidance for Slice Testing Approach in Diagnostics